Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III randomized double-blind study of tiragolumab plus atezolizumab vs placebo plus atezolizumab as adjuvant therapy in PD-L1 positive resected non-small cell lung cancer
CTR20240140Phase 3Completed
- Sponsor
- Roche
- Start
- Jan 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of tiragolumab in non-small cell lung cancer (NSCLC), sponsored by Roche. Started Jan 2024; status: completed.
02
Drugs
tiragolumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20240140.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20240140.